ArticleAlzheimer's & dementia (New York, N. Y.)
Creatine monohydrate pilot in Alzheimer's: Feasibility, brain creatine, and cognition.
Article in Alzheimer's & dementia (New York, N. Y.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05383833 (Creatine to Augment Bioenergetics in Alzheimer's), which is not on this map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Creatine to Augment Bioenergetics in Alzheimer's
Who cites it
12 citing papers in PubMed.
- Effects of creatine supplementation with and without exercise and diet intervention on body composition, cognitive function, and markers of health in middle-aged and older adults.Journal of the International Society of Sports Nutrition · 2026Trial
- Single-Dose Creatine Reduces Sleep Deprivation-Induced Deterioration in Cognitive Performance.Nutrients · 2026Trial
- A peripheral perspective on brain health: vascular and skeletal muscle contributions.American journal of physiology. Heart and circulatory physiology · 2026Review
- Redirecting Alzheimer's disease therapeutics: Multitarget drugs and complementary non-pharmacological strategies.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Review
- Dysregulated glucose metabolism in the visual cortex of human subjects with mild cognitive impairment and Alzheimer's disease.Frontiers in aging neuroscience · 2026Article
- Joint effects of leukocyte-albumin ratio and hypertension are associated with multidimensional cognitive decline and Alzheimer's disease risk in older adults: evidence from NHANES and a clinical AD validation cohort.Frontiers in aging neuroscience · 2026Article
- Creatine monohydrate supplementation for older adults and clinical populations.Journal of the International Society of Sports Nutrition · 2025Review
- Are Hippocampal Hypoperfusion and ATP Depletion Prime Movers in the Genesis of Alzheimer's Disease? A Review of Recent Pertinent Observations from Molecular Biology.International journal of molecular sciences · 2025Review
- Eight weeks of creatine monohydrate supplementation is associated with increased muscle strength and size in Alzheimer's disease: data from a single-arm pilot study.Frontiers in nutrition · 2025Article
- A Food-First Prescription for Cognitive Longevity.Missouri medicineArticle
- Bioenergetic data from a creatine monohydrate pilot trial in Alzheimer's disease.Alzheimer's & dementia (New York, N. Y.)Article
- Creatine monohydrate pilot in Alzheimer's: Feasibility, brain creatine, and cognition.Alzheimer's & dementia (New York, N. Y.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundPreclinical studies suggest that creatine monohydrate (CrM) improves cognition and Alzheimer's disease (AD) biomarkers. However, there is currently no clinical evidence demonstrating the effects of CrM in patients with AD.
methodsIn this single-arm pilot trial, we investigated the feasibility of 20 g/day CrM for 8 weeks in 20 patients with AD. We measured compliance throughout; serum creatine at baseline, 4 weeks, and 8 weeks; and brain total creatine (tCr) and cognition (National Institutes of Health [NIH] Toolbox, Mini-Mental State Examination [MMSE]) at baseline and 8 weeks.
resultsNineteen participants achieved the target of ≥80% compliance with the CrM intervention. Serum Cr was elevated at 4 and 8 weeks ( DISCUSSION: Our data suggest that CrM supplementation is feasible in AD and provides preliminary evidence for future efficacy and mechanism studies. Trial Registration: ClinicalTrials.gov, NCT05383833, registered on May 20, 2022. Highlights: Creatine monohydrate supplementation was feasible in patients with Alzheimer's disease.Creatine monohydrate was associated with increased brain total creatine.Creatine monohydrate was associated with improvements in cognition.Efficacy of creatine monohydrate in Alzheimer's disease should be studied further.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.